Emerging Treatments Flashcards

1
Q

How do errors in metabolism lead to disease

A

Lacks enzyme
Can’t make product
Leads to excess substrate
Leads to alternative product which may cause disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Examples of metabolic error diseases

A

PKU ( Protein Ketone Urea)
MCAD Deficiency
Maple Syrup urine disease
Homocystinuria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

PKU ( phenylketonuria) cause

A

Caused by a lack of phenylalanine hydroxylase ( enzyme) and this leads to the creation of phenylketones which are neurotoxic and kills brain cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Symptoms of untreated PKU

A
Major cognitive impairment 
Behavioural difficulties
Fairer skin , hair and eyes than siblings
Lack of melanin 
Recurrent vomiting
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Treatment of PKU

A

Treatment with low protein diet - tyrosine supplements

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Haemophilia symptoms

A
Uncontrolled bleeding 
Bleeding into joints
Excruciating pain 
Bleeding into brain 
Internal bleeding

Can be fatal if untreated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Haemophilia treatment

A

Fresh Frozen Plasma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Solutions to contaminated blood scandals for FFP

A

Heat treat products kills virus
Factor 8 can be cloned
Recombinant factor 7 treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Pompe disease treatment

A

Injection of alpha glucosidase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Lysol also storage disease

A

Injection recombinant alpha galactosidase A/ agalsisase beta ( faradenzyme)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Do therapies targeting proteins cure the disease

A

No they are treatments not cures as they try to normalise the function of mutant proteins - they treat the condition not the symptoms so need to take these treatments for as long as you live

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are pharmacological chaperones

A

Protein folding is complex sometime fails
System in endoplasmic reticulum degrades misfolded proteins
Some mutations prevent proteins folding properly > so they are subject degradation pathway
If folded correctly would be active
Chaperones can stabilise the shape of the protein so it folds properly and does not get degraded. (It’s acts as a competitor to the original defective enzyme)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Example of a pharmacological chaperone

A

Fairy disease - deficiency of alpha galactosidase A
Build up of glonotriaosylceramide
Some mutations cause misfolding of proteins
Migalastat small molecule chaperone
Stabilises enzyme in correct shape

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Pharmacological modulators

A

Pharmacological modulators are commonly used drugs
Receptor agonists/antagonist
Ion channel activators/blockers
Can design one that has these effects on mutant receptor or channel
Bcl-abl Kinase inhibitors (Philadelphia chromosome)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Cystic fibrosis

A

Defective chloride channel
Mutations (33) cause channel not to open
Design a drug which causes activation - Ivacaftor
Is mutation specific

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Example of combination therapy

A

Cystic fibrosis
Defective chloride channel + One mutation (f508del) misfolded, inactive channel
Treat with combination chaperone and activator (turns it on in situations when it wouldn’t be on)
Orkambi (Ivacaftor/lumacaftor) – NICE approved Oct ’19
Not cure but does improve lung function

17
Q

Diseases caused by stop codon read through

A

Some diseases are caused by non sense mutations where there is a premature stop codon
This prevents protein production

18
Q

Example of a drug which treats non sense mutation

A

Mutation causes release factors to bind prematurely and so there is a shorter protein formed. Aminoglycoside antibiotics bind to the ribosome and causes mistranslation . Drugs based on these prevent the release factors from binding and so a full length DNA is produced

Aminoglycoside Abs is an example as it binds to ribosome causing mistranslation so skip the nonsense in a loss of function

19
Q

Duchenne muscular dystrophy

A

DMD premature stop codon and Becker Muscular dystrophy has a missing section

If read through premature stop codon DMD-> BMD
Atalurenis an example
But it is non sense mutation specific and so doesn’t cure but reduces the symptoms

20
Q

In vivo

A

In living

21
Q

Ex vivo

A

Out of the living

22
Q

In vitro

A

In glass ( foetus)

23
Q

How to fix a recessive diseases by gene therapy

A

Recessive disease - rePlace defective gene

Dominant disease - delete defective gene

24
Q

Why is in vivo hard

A
Very difficult to achieve in practice
	Achieving specificity
	Getting therapy to right place
	Maintaining expression
Much easier to achieve in vitro than in vivo

In vivogene therapy means that therapy is administered directly the patient. The targeted cells remain in the body of the patient. Withex vivogene/cell therapy the targeted cells are removed from the patient and gene therapy is administered to the cellsin vitrobefore they are returned to the patient’s body.

25
Q

How does mitochondrially inherited disease therapy work

A

It is ex vivo / in vitro

Only effective therapy
Requires IVF
Take DNA from fertilised patient egg
Transfer to donor egg normal mitochondria

26
Q

Virus gene therapy

A
Can Engineer virus to carry therapeutic gene
Wide variety of virus used
	AAV
	Adenovirus
	Lentivirus – HIV 
	Vaccinia

Virus choice depends on target tissue : virus tropism has affinity of injecting certain viral phenotypes
Amount of DNA limited depends on virus

27
Q

In vitro gene therapy SCID

A

X linked
Can be treated with bone marrow transplant as it is caused by adenosine dealings deficiency

But not possible for all children (90% ADa -SCID) no match
Has own risks

28
Q

Process of treating in vitro gene therapy ADa -SCID

A
Strimevelis
Autologous transplant
Isolate patients Haemopoietic stem cells 
Isolate and expand CD34+ 
Transferred with ADA -lentivirus 
Grow transformed cells
Treat patient with busulfan (kills HSC) 
Reinfused transformed cells into patients
29
Q

In vivo therapy supplement

A

Lever congenital amaurosis type 2
Recessive disease caused by mutation REP65
Progressive blindness - loss of rentinal cells
Luxturna rAAV2 expressing RPE65
Not cure ; greatly improves vision
Patients need sufficient remaining cells

30
Q

Anti sense oligonucleotides

A

Shortnmodifies nucleic acid complementary to target
Modification prevents degredation allow entry to cell
Binds to target
Block translation
Can also alter splicing
Relatively cheap

31
Q

In vivo therapy knockdown

A

Useful for disease caused by gain of function
Inotersen -
Transthyretin- related hereditary amyloidosis
Mutation in transthyretin ( TTH)
TTH cannot form tetramers , forms aggregates
Mutation specific

32
Q

Transthyretin related hereditary amyloidosis

A

Symptoms between 20-40
Pain muscle weakness and this eventually leads to heart and brain problems
Insotersen binds to wildtype mRNA and stop production /slows down overall rate of production

33
Q

Exon skipping

A

During pre-RNA processing
Oligonucleotides cause exon to be skipped
Can be used to skip disease causing exon
To put RNA back in reading-frame

Useful in limited circumstances
Exons skipped mustn’t be vital otherwise worse damage
Generally only large proteins - small proteins will lose too much

34
Q

Exon skipping in duchenne muscular dystrophy

A

Duchenne muscular dystrophy – premature stop (nonsense)
Becker muscular dystrophy – missing section
If prevent incorporation mutant exon DMD → BMD
It skips an exon and moves it back into frame.

35
Q

Drug used to treat exon skipping in duchenne muscular dystrophy

A

Eteplirsen – oligonucleotide cause skipping exon 51

Will result in production partially active dystrophin

36
Q

Gene editing CRISPR- Cas 9

A

Bacterial system disable bacteriophages

Clustered Regularly Interspaced Short Palindromic Repeats
CRISPR – derived from previous bacteriophage
CAS9- Crispr associated protein 9- Endonuclease
Recognises and Cleaves DNA CRISPR hybrids

Gene editing correct relatively small errors
Cannot correct large changes
Large deletions OR triplet expansion

May have off target effects
Not currently used in humans (1 exception)
Same problem as other methods
	Targeting
	Getting into cell